Ipsen to acquire ImCheck Therapeutics to strengthen oncology pipeline
The acquisition centers on ImCheck’s lead Phase I/II program, ICT01, a first-in-class monoclonal antibody targeting BTN3A
The acquisition centers on ImCheck’s lead Phase I/II program, ICT01, a first-in-class monoclonal antibody targeting BTN3A
Takeda will make an upfront payment of $1.2 billion, which includes a $100 million equity investment in Innovent
Breakthrough expands proactive TB screening from birth to 15 years, ensuring faster and more accurate diagnosis
Based on these promising results, Johnson & Johnson plans to move the program into a Phase 3 trial to further investigate subcutaneous amivantamab
Contera Pharma will receive an upfront payment and full research funding for each target under investigation
This new facility strengthens Latin America as a collaborative hub
Triamcinolone Acetonide injectable suspension USP is indicated for various autoimmune, inflammatory, and other conditions
With this expansion, the overall fermentation capacity of the company has increased from 450 KL to 990 KL
IKS Health's innovative solution orchestrates a roll out of critical operations functions into a unified and efficient connected workflow
Novelix will provide financial and infrastructural support for the entire technology transfer and scale-up program
        Subscribe To Our Newsletter & Stay Updated